226 related articles for article (PubMed ID: 26303103)
1. Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws.
Mawardi H; Glotzbecker B; Richardson P; Woo SB
Biol Blood Marrow Transplant; 2016 Feb; 22(2):344-348. PubMed ID: 26303103
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
3. Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study.
Wazzan T; Kashtwari D; Almaden WF; Gong Y; Chen Y; Moreb J; Katz J
Spec Care Dentist; 2018 Nov; 38(6):356-361. PubMed ID: 30194738
[TBL] [Abstract][Full Text] [Related]
4. The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection.
Russmueller G; Seemann R; Weiss K; Stadler V; Speiss M; Perisanidis C; Fuereder T; Willinger B; Sulzbacher I; Steininger C
Sci Rep; 2016 Aug; 6():31604. PubMed ID: 27530150
[TBL] [Abstract][Full Text] [Related]
5. Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study.
Zhou Y; Yu Y; Shi Y; Li M; Yang C; Wang S
Biomed Res Int; 2020; 2020():5847429. PubMed ID: 33123580
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
Migliorati CA; Siegel MA; Elting LS
Lancet Oncol; 2006 Jun; 7(6):508-14. PubMed ID: 16750501
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws.
Klingelhöffer C; Zeman F; Meier J; Reichert TE; Ettl T
J Craniomaxillofac Surg; 2016 Oct; 44(10):1694-1699. PubMed ID: 27591091
[TBL] [Abstract][Full Text] [Related]
8. Selective Percutaneous Controlled Radiofrequency Thermocoagulation of the Gasserian Ganglion To Control Facial Pain Due to Medication-Related Osteonecrosis of the Jaw.
Taniguchi A; Fukazawa K; Hosokawa T
J Palliat Med; 2017 Oct; 20(10):1171-1174. PubMed ID: 28772087
[TBL] [Abstract][Full Text] [Related]
9. Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): report of 4 cases.
Lee CY; Suzuki JB
Implant Dent; 2015 Apr; 24(2):227-31. PubMed ID: 25734948
[TBL] [Abstract][Full Text] [Related]
10. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients.
Soutome S; Otsuru M; Hayashida S; Murata M; Yanamoto S; Sawada S; Kojima Y; Funahara M; Iwai H; Umeda M; Saito T
Sci Rep; 2021 Aug; 11(1):17226. PubMed ID: 34446755
[TBL] [Abstract][Full Text] [Related]
11. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
12. Differences between osteoradionecrosis and medication-related osteonecrosis of the jaw.
Akashi M; Wanifuchi S; Iwata E; Takeda D; Kusumoto J; Furudoi S; Komori T
Oral Maxillofac Surg; 2018 Mar; 22(1):59-63. PubMed ID: 29224060
[TBL] [Abstract][Full Text] [Related]
13. Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
Movila A; Mawardi H; Nishimura K; Kiyama T; Egashira K; Kim JY; Villa A; Sasaki H; Woo SB; Kawai T
Biochem Biophys Res Commun; 2016 Nov; 480(1):42-47. PubMed ID: 27720716
[TBL] [Abstract][Full Text] [Related]
14. Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience.
Taş Ozyurtseven B; Serin I; Nursal AF; Pehlivan S; Pehlivan M
BMC Oral Health; 2021 May; 21(1):272. PubMed ID: 34006261
[TBL] [Abstract][Full Text] [Related]
15. Surgical Therapy for Bisphosphonate-Related Osteonecrosis of the Jaw: Six-Year Experience of a Single Institution.
Lopes RN; Rabelo GD; Rocha AC; Carvalho PA; Alves FA
J Oral Maxillofac Surg; 2015 Jul; 73(7):1288-95. PubMed ID: 25871903
[TBL] [Abstract][Full Text] [Related]
16. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously?
Junquera S; Álvarez-Yagüe E; Junquera L; Ugalde R; Rúa L
J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):523-526. PubMed ID: 31863926
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
Edwards BJ; Gounder M; McKoy JM; Boyd I; Farrugia M; Migliorati C; Marx R; Ruggiero S; Dimopoulos M; Raisch DW; Singhal S; Carson K; Obadina E; Trifilio S; West D; Mehta J; Bennett CL
Lancet Oncol; 2008 Dec; 9(12):1166-72. PubMed ID: 19038763
[TBL] [Abstract][Full Text] [Related]
20. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
Mignogna MD; Fedele S; Lo Russo L; Ciccarelli R; Lo Muzio L
J Clin Oncol; 2006 Mar; 24(9):1475-7. PubMed ID: 16549843
[No Abstract] [Full Text] [Related]
[Next] [New Search]
